SUN PHARMACEUTICAL INDUSTRIES LIMITED

Corporate Identity Number (CIN): L24230GJ1993PLC019050

Registered Office: Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara - 390 012, Gujarat, India.
Corporate Office: SUN House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400 063, Maharashtra, India.
Phone: +91 22 4324 4324 | **Fax:** +91 22 4324 4343 | **E-mail ID:** secretarial@sunpharma.com | **Website:** www.sunpharma.com
Contact Persons : Mr. Ashok I Bhuta (*Compliance Officer*) | Mr. Sunil Ajmera (*Company Secretary & Compliance Officer*)

POST BUY-BACK PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/BENEFICIAL OWNERS OF EQUITY SHARES OF SUN PHARMACEUTICAL INDUSTRIES LIMITED ("Company")

This Public Announcement ("**Post Buy-back Public Announcement**") is released in compliance with the provisions of Regulation 24(vi) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("**Buy-back Regulations**"). This Post Buy-back Public Announcement should be read in conjunction with the public announcement dated March 18, 2020 (**"Public Announcement"**) read with Corrigendum to Public Announcement dated March 24, 2020 ("**Corrigendum**"). The terms used but not defined in this Post Buy-back Public Announcement shall have the same meaning as assigned to such terms in the Public Announcement read with the Corrigendum.

1. THE BUY-BACK

1.1. The Board of Directors of Sun Pharmaceutical Industries Limited (hereinafter referred to as the "**Board**"), at its meeting held on March 17, 2020 ("**Board Meeting**") had, pursuant to the provisions of Article 9 of Articles of Association of the Company and Sections 68, 69 and 70 and all other applicable provisions of the Companies Act, 2013 ("**Act**") and applicable rules made thereunder and in compliance with the Buy-back Regulations and subject to such other approvals permissions and sanctions as may be necessary, approved the buy-back of fully paid up equity shares by the Company having face value of ₹1/- (Indian Rupee One Only) each ("**Equity Share(s)**") from open market through stock exchange mechanism as prescribed under the Buy-back Regulations from the equity shareholders / beneficial owners of the Equity Shares of the Company other than the promoter, members of promoter group and persons acting in concert of the Company ("**Promoter and Persons in Control**"), at a price not exceeding ₹425/- (Indian Rupees Four Hundred Twenty Five Only) per Equity Share ("**Maximum Buy-back Price**") payable in cash for an aggregate amount not exceeding ₹1700,00,00,000/- (Indian Rupees One Thousand Seven Hundred Crores Only) excluding transaction costs viz. brokerage, advisor's fees, intermediaries fees, public announcement publication fees, filling fees, turnover charges, applicable taxes such as securities transaction tax, goods and services tax, income tax, stamp duty and other incidental and related expenses ("**Transaction Costs**") ("**Maximum Buy-back Size**").

1.2. The Buy-back commenced on Thursday, March 26, 2020 and closed on Friday, September 25, 2020 (both days inclusive).

1.3. Till the date of closure of the Buy-back, the Company has bought back **Nil** Equity Shares. No Equity Shares have been bought back under the Buy-back as the volume weighted average market price of Equity Shares of the Company during the buy-back period was higher than the Maximum Buy-back Price.

2. DETAILS OF BUY-BACK

Particulars	Details
Number of Equity Shares bought back	Nil
Price at which Equity Shares were bought back	Not Applicable
Total Amount invested in Buy-back (excluding Transaction Costs)	Nil
Details of Equity Shareholders from whom Equity Shares exceeding one percent of total Equity Shares were bought back	Not Applicable as the Buy-back was from Open Market through Stock Exchange Mechanism

3. CAPITAL STRUCTURE AND SHAREHOLDING PATTERN

3.1. The pre and post Buy-back Capital structure of the Company is as under:

(₹ in Crores)

Particulars	Pre Buy-back	Post Buy-back
Authorized Share Capital		
599,00,00,000 Equity Shares of ₹ 1/- each	599.00	599.00
1,00,000 Preference Shares of ₹ 100/- each	1.00	1.00
Total	**600.00**	**600.00**
Issued, subscribed and fully paid up :		
239,93,34,970 Equity Shares of ₹ 1/- each	239.93	239.93
Total	**239.93**	**239.93**

3.2. The shareholding pattern of the Company, pre and post Buy-back, is as under:

Particulars	Pre Buy-back#		Post Buy-back	
	Number of Equity Shares held	% of the equity share capital	Number of Equity Shares held	% of the equity share capital
(A) Promoter and Promoter Group	**1,31,21,34,535**	**54.69**	**1,31,21,34,535**	**54.69**
(B) Public Shareholders				
Institutions	77,44,34,761	32.28	**1,08,72,00,435**	**45.31**
Central Government / State Government(s) / President of India	6,430	0.00		
Non-Institutions	31,27,59,244	13.03		
Sub-Total	**1,08,72,00,435**	**45.31**		
(C) Non Promoter – Non Public	**Nil**	**Nil**	**Nil**	**Nil**
Total	**2,39,93,34,970**	**100.00**	**2,39,93,34,970**	**100.00**

\# As on March 17, 2020 viz. the date of Board Meeting approving the Buy-back

4. MANAGER TO THE BUY-BACK

VIVRO

VIVRO FINANCIAL SERVICES PRIVATE LIMITED
607, 608 Marathon Icon, Opp. Peninsula Corporate Park, Off Ganpatrao Kadam Marg,
Veer Santaji Lane, Lower Parel, Mumbai – 400 013, Maharashtra, India.
Contact Person: Mr. Harish Patel / Mr. Bhargav Parekh
Email: investors@vivro.net | **Website:** www.vivro.net
Tel: +91 22 6666 8040/41/42 | **Fax:** +91 22 6666 8047
SEBI Registration Number: INM000010122 | **Validity:** Permanent
CIN: U67120GJ1996PTC029182

5. LEGAL ADVISOR TO THE COMPANY

Bathiya Legal
909, Hubtown Solaris, N. S. Phadke Road, Near East - West Flyover,
Andheri (East), Mumbai – 400 069, Maharashtra, India. | Tel: +91 22 6133 8050

6. DIRECTOR'S RESPONSIBILITY

As per Regulation 24(i)(a) of the Buy-back Regulations, the Board accepts responsibility for the information contained in this Post Buy-back Public Announcement and confirms that it is true, factual and does not contain any misleading information.

For and on behalf of the Board of Directors of Sun Pharmaceutical Industries Limited

Sd/-	Sd/-	Sd/-
Dilip S. Shanghvi	**Sailesh T. Desai**	**Sunil R. Ajmera**
Managing Director	**Whole-time Director**	**Company Secretary**
(DIN: 00005588)	**(DIN: 00005443)**	**(Membership Number: A12176)**
Place: Mumbai	**Place:** Vadodara	**Place:** Mumbai

Date: September 25, 2020

Raka